Fundz

Fundz Deep Dive

Everything you need to win Aspect Biosystems — in one platform.

Who to reach, what to say, and why now on Aspect Biosystems — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Aspect Biosystems — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

Aspect Biosystems partners with Dimension and Novo Nordisk in $115M funding round

Jan 08, 2025•over 1 year ago

Contract Type

partnership

VancouverBiotechnologyHealth Care

Description

Vancouver-based Aspect Biosystems has announced a Series B financing of $115 million led by Dimension and involving participation from Novo Nordisk, Radical Ventures, InBC, Pallasite Ventures, Pangaea Ventures, Rhino Ventures, and T1D Fund. The funding will drive the clinical trial for bioprinted tissue and expand AI-driven therapeutic technologies.

Company Information

Company

Aspect Biosystems

Location

Vancouver, British Columbia, Canada

About

Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat some of the most elusive diseases. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body. Aspect is creating these next-generation cell therapies by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, computational design tools, therapeutic cells, and advanced biomaterials. Aspect is advancing a pipeline of bioprinted tissue therapeutics across multiple disease areas in the endocrine and metabolic space including diabetes, obesity, rare endocrine disorders, and liver disease. Aspect's pipeline development strategy involves both proprietary programs as well as strategic partnerships, including a collaboration with Novo Nordisk focused on diabetes and obesity.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Aspect Biosystems's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.